Laboratorios Farmaceuticos Rovi Overview
Pro stress-test →Laboratorios Farmaceuticos Rovi specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. The company has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products. As a Spanish pharmaceutical leader, Rovi serves cardiology, CNS, respiratory, and diagnostic imaging markets with both proprietary formulations and biosimilars.
Strategic Profile
Pro stress-test →Rovi's flagship product Bemiparin is present in 89 countries, and the company markets an enoxaparin biosimilar developed in-house across 38 countries. Rovi continues to develop the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release with proven advantages. The company leverages vertical integration, proprietary manufacturing capabilities, and international expansion to compete in competitive specialty pharma and contract manufacturing markets.
Competitive Landscape
Pro stress-test →Rovi competes in the European specialty pharmaceuticals and contract manufacturing sectors against both large multinational pharma companies and mid-cap players. Key Spanish/European competitors include Almirall, Faes Farma, and Reig Jofre, as well as larger contract manufacturing players. Rovi's differentiation stems from its biosimilar portfolio (Bemiparin, Enoxaparin), proprietary ISM platform technology, and integrated manufacturing capabilities serving cardiology, diagnostics, and CNS markets.
Industry Context
Laboratorios Farmaceuticos Rovi operates in Specialty Pharmaceuticals & Contract Manufacturing.
Key facts
Founded: 1946 · Headquarters: Madrid, Spain · Revenue: €763.75M (2024) · Market cap: €2.84B